SM Merger/Arbitrage, L.P. et al v. Bristol-Myers Squibb Company et al

Track this case

Case Number:

1:21-cv-08255

Court:

New York Southern

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

Jesse M. Furman

Firms

Companies

Sectors & Industries:

  1. March 01, 2024

    NY Judge Tosses $6.4B BMS Investor Action For Good

    Celgene Corp. investors could not convince a New York federal judge that Bristol-Myers Squibb Co. was intentionally trying to flout securities law by delaying the U.S. Food and Drug Administration's approval of a cancer treatment in order to avoid giving them a $6.4 billion payout. 

  2. March 01, 2023

    Bristol-Myers Slips Suit Over $6.4B Investor Payment, For Now

    A Manhattan federal judge Wednesday dismissed a proposed class action alleging Bristol-Myers Squibb Co. and its executives intentionally delayed the U.S. Food and Drug Administration's approval of a cancer treatment developed by subsidiary Celgene Corp. to avoid making a $6.4 billion payment to investors.